Immune Checkpoint Inhibitors - NCI - National Cancer Institute
网页Blocking the binding of PD-L1 to PD-1 with an immune checkpoint inhibitor (anti-PD-L1 or anti-PD-1) allows the T cells to kill tumor cells (right panel). Credit: © Terese Winslow. On This Page. How do immune checkpoint inhibitors work against cancer? Which cancers are treated with immune checkpoint inhibitors?
Article Fusobacterium nucleatum facilitates anti-PD-1 therapy in ...
网页2 天之前 · To examine the role of Fn in modulating anti-PD-1 efficacy in patients with MSS CRC, we recruited 25 patients with MSS CRC who underwent anti-PD-1 therapy (Table S1), and their pretreatment fecal or intratumoral Fn abundance was determined by qPCR. Fn abundance was positively correlated with progression-free survival and overall survival of patients with MSS CRC treated with anti-PD-1 (Figure ...
Anti-PD-1 cis-delivery of low-affinity IL-12 activates ... - Nature
网页2024年6月3日 · Anti-PD1-mIL12mut2 preferentially binds to tumor-infiltrating PD-1 + CD8 + T cells. Persistent antigen stimulation in tumors promoted much higher levels of PD-1 expression on TILs...
Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the ...
网页2020年2月7日 · Treatment with anti-PD-1/PD-L1 inhibitors is the preferred approach for patients with advanced or metastatic cancer. After examining individual data from 35 RCTs, we revealed that...
Effects of anti-PD-1 immunotherapy on tumor regression ... - Nature
网页2020年4月27日 · Immunotherapies, such as checkpoint blockade of programmed cell death protein-1 (PD-1), have resulted in unprecedented improvements in survival for patients with lung cancer.
The progress and challenge of anti-PD-1/PD-L1 immunotherapy …
网页2021年2月15日 · The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1) inhibitors is the standard therapy for the first-line or second-line treatment of patients with non-small-cell lung cancer (NSCLC).
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody …
网页2012年6月28日 · Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that...
Real-World Outcomes of First-Line Treatment With Anti–PD(L)1 …
网页Eligible physicians in the United States, Europe, and Japan abstracted information from medical charts of eligible adult patients with mnsqNSCLC (without EGFR/ALK, no known ROS1 alterations) who initiated 1L anti–PD(L)1-based combination therapy for mnsqNSCLC between 2017 and 2021. Kaplan-Meier analyses were used to assess overall survival (OS), time-to-treatment discontinuation (TTD), and ...
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and …
网页2015年9月1日 · This therapy is distinct from the prior immune therapeutic agents, which primarily boost systemic immune responses or generate de novo immunity against cancer; instead, anti-PD therapy modulates immune responses at the tumor site, targets tumor-induced immune defects, and repairs ongoing immune responses.
Nature Cancer | 张泽民课题组与合作者揭示anti-PD-1免疫治疗在 …
网页为了促进下一代免疫治疗的发展，首先需要清楚anti-PD-1治疗的作用机制。. 研究人员收集了anti-PD-1治疗前后的肺癌患者的肿瘤样本，利用单细胞测序系统地追踪了T细胞在治疗前后的动态变化，并分析了有响应患者和无响应患者之间的差异（图1）。. 图1 课题研究 ...
跳至内容